Drug desensitization: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz No edit summary |
mNo edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 5: | Line 5: | ||
| journal = Wake Forest School of Medicine}}</ref> | | journal = Wake Forest School of Medicine}}</ref> | ||
It is primarily directed at Type I, or [[ | It is primarily directed at Type I, or [[Immunoglobulin E|immunoglobulin E]]-mediated, in the [[Gell and Coombs classification of immune reactions]]. The interaction of these with the drug causes degranulation of [[basophil]]s and [[mast cell]]s, which release or produce immune mediators such as [[histamine]], [[prostaglandin]]s, and [[leukotriene]]s. <ref>{{citation | ||
| title = Hypersensitivity Reactions, Immediate | |||
| author = Miriam K Anand and John M Route | journal = eMedicine | |||
| date = 21 April 2010 | |||
| url = http://emedicine.medscape.com/article/136217-overview}}</ref> | |||
==References== | |||
{{reflist}}[[Category:Suggestion Bot Tag]] | |||
Latest revision as of 06:00, 9 August 2024
Drug desensitization is a technique for suppressing dangerous immune reactions to specific drugs, such that the drug may be used for treatment. It uses different approaches than allergy desensitization, intended to produce long-term effects. [1]
It is primarily directed at Type I, or immunoglobulin E-mediated, in the Gell and Coombs classification of immune reactions. The interaction of these with the drug causes degranulation of basophils and mast cells, which release or produce immune mediators such as histamine, prostaglandins, and leukotrienes. [2]
References
- ↑ "Drug Desensitization", Wake Forest School of Medicine
- ↑ Miriam K Anand and John M Route (21 April 2010), "Hypersensitivity Reactions, Immediate", eMedicine